BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12949795)

  • 1. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma.
    Guan X; Sagara J; Yokoyama T; Koganehira Y; Oguchi M; Saida T; Taniguchi S
    Int J Cancer; 2003 Nov; 107(2):202-8. PubMed ID: 12949795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer.
    Yokoyama T; Sagara J; Guan X; Masumoto J; Takeoka M; Komiyama Y; Miyata K; Higuchi K; Taniguchi S
    Cancer Lett; 2003 Dec; 202(1):101-8. PubMed ID: 14643031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer.
    Virmani A; Rathi A; Sugio K; Sathyanarayana UG; Toyooka S; Kischel FC; Tonk V; Padar A; Takahashi T; Roth JA; Euhus DM; Minna JD; Gazdar AF
    Int J Cancer; 2003 Aug; 106(2):198-204. PubMed ID: 12800194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma.
    Stone AR; Bobo W; Brat DJ; Devi NS; Van Meir EG; Vertino PM
    Am J Pathol; 2004 Oct; 165(4):1151-61. PubMed ID: 15466382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers.
    Conway KE; McConnell BB; Bowring CE; Donald CD; Warren ST; Vertino PM
    Cancer Res; 2000 Nov; 60(22):6236-42. PubMed ID: 11103776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of metallothionein 1A gene in melanoma.
    Nobeyama Y; Nakagawa H
    J Dermatol Sci; 2017 Nov; 88(2):232-237. PubMed ID: 28764861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions.
    Sharma BK; Smith CC; Laing JM; Rucker DA; Burnett JW; Aurelian L
    Dermatology; 2006; 213(3):192-9. PubMed ID: 17033167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture.
    Stimson KM; Vertino PM
    J Biol Chem; 2002 Feb; 277(7):4951-8. PubMed ID: 11733524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of methylation on expression of TMS1/ASC in human breast cancer cells.
    Levine JJ; Stimson-Crider KM; Vertino PM
    Oncogene; 2003 May; 22(22):3475-88. PubMed ID: 12776200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic down-regulation of death-associated protein kinase in lung cancers.
    Toyooka S; Toyooka KO; Miyajima K; Reddy JL; Toyota M; Sathyanarayana UG; Padar A; Tockman MS; Lam S; Shivapurkar N; Gazdar AF
    Clin Cancer Res; 2003 Aug; 9(8):3034-41. PubMed ID: 12912953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of TMS1/ASC in ovarian cancer.
    Terasawa K; Sagae S; Toyota M; Tsukada K; Ogi K; Satoh A; Mita H; Imai K; Tokino T; Kudo R
    Clin Cancer Res; 2004 Mar; 10(6):2000-6. PubMed ID: 15041718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual role of TMS1/ASC in death receptor signaling.
    Parsons MJ; Vertino PM
    Oncogene; 2006 Nov; 25(52):6948-58. PubMed ID: 16715133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
    Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide inhibits DNA methyltransferase and restores TMS1 gene expression in K562 cells.
    Li H; Wang Y; Xu W; Dong L; Guo Y; Bi K; Zhu C
    Acta Haematol; 2015; 133(1):18-25. PubMed ID: 24993472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells.
    Wada K; Maesawa C; Akasaka T; Masuda T
    J Invest Dermatol; 2004 Mar; 122(3):805-11. PubMed ID: 15086568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX4 has the potential to function as a tumor suppressor in human melanoma.
    Hata S; Hamada J; Maeda K; Murai T; Tada M; Furukawa H; Tsutsumida A; Saito A; Yamamoto Y; Moriuchi T
    Int J Oncol; 2008 Nov; 33(5):1065-71. PubMed ID: 18949370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas.
    Tanaka H; Shimada Y; Harada H; Shinoda M; Hatooka S; Imamura M; Ishizaki K
    Cancer Res; 1998 Aug; 58(15):3429-34. PubMed ID: 9699676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
    Bae SI; Cheriyath V; Jacobs BS; Reu FJ; Borden EC
    Oncogene; 2008 Jan; 27(4):490-8. PubMed ID: 17653094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.